NM_001042432.2(CLN3):c.500T>A (p.Val167Asp)

For CLN3 c.500T>A (p.Val167Asp), a pathogenic missense variant in the CLN3/battenin transmembrane protein that causes juvenile neuronal ceroid lipofuscinosis (JNCL/CLN3 Batten disease), intrathecal AAV-mediated CLN3 gene delivery represents the primary gene therapy strategy under investigation. Unlike soluble lysosomal enzymes (which benefit from cross-correction via secretion-recapture), CLN3 is a transmembrane protein localized to lysosomes and endosomes that cannot be secreted and taken up by neighboring cells. This fundamental biology means that each neuron must be individually transduced, making delivery and biodistribution the central challenge. Val167 is in a transmembrane domain; the V167D substitution introduces a charged residue into the lipid bilayer, likely destabilizing membrane insertion.

Weimer et al. (2021) demonstrated that intrathecal AAV9-CLN3 injection in Cln3-null mice reduced lysosomal storage material, improved neuroinflammatory markers, and partially preserved motor function. The AAV gene therapy program for CLN3 Batten disease is being developed with support from the Batten Disease Support and Research Association. For CLN2 (a related NCL caused by soluble enzyme TPP1 deficiency), cerliponase alfa (Brineura, intracerebroventricular enzyme replacement) received FDA approval in 2017, providing precedent for CNS-directed therapies in NCLs — but this ERT approach is not applicable to CLN3 due to the transmembrane nature of battenin. The natural history of JNCL includes progressive vision loss (typically age 4-7), seizures, cognitive decline, and death in the second to third decade. No disease-modifying therapy is currently approved.

The transmembrane nature of CLN3 protein precludes cross-correction between cells, meaning that therapeutic benefit is directly proportional to the fraction of neurons transduced — a much higher transduction threshold than for secreted lysosomal enzymes. Achieving near-complete CNS transduction via intrathecal AAV is currently not feasible; typical transduction rates reach 10-30% of neurons depending on serotype, dose, and injection route. The progressive nature of JNCL means treatment must be initiated before substantial neuronal loss; by the time of clinical diagnosis (often age 5-8 after vision loss), significant damage has occurred. For p.Val167Asp specifically, this missense variant may produce a protein that is synthesized but mistrafficked — if the mutant protein is retained in the ER rather than reaching lysosomes, there may be an ER stress component to pathology not fully addressed by wild-type CLN3 delivery to other cells. Immunosuppression regimens and durability of intrathecal AAV expression remain under investigation. No CLN3 gene therapy has entered human clinical trials as of early 2026.